The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Open accessAbstract
The priming of tumor-antigen-specific T cells is critical for the initiation of successful anti-tumor immune responses, yet the fate of such cells during tumor progression is unknown. Naive CD4+T cells specific for an antigen expressed by tumor cells were transferred into tumor-bearing mice. Transient clonal expansion occurred early after transfer, accompanied by phenotypic changes associated with antigen recognition. Nevertheless, these cells had a diminished response to peptide antigen in vitro and were unable to be primed in vivo. The development of antigen-specific T cell anergy is an early event in the tumor-bearing host, and it suggests that tolerance to tumor antigens may impose a significant barrier to therapeutic vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Antigen-specific interaction between T and B cells
Lanzavecchia, A. (1985) · Nature · doi:10.1038/314537a0 · Cited by 1,412
The B7 and CD28 receptor families
June, C. H., Bluestone, J. A., Nadler, L. M., & Thompson, C. B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90080-9 · Cited by 1,296
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
Kearney, E. R., Pape, K. A., Loh, D. Y., & Jenkins, M. K. (1994) · Immunity · doi:10.1016/1074-7613(94)90084-1 · Cited by 946
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Induction of Peripheral T Cell Tolerance In Vivo Requires CTLA-4 Engagement
Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B., & Abbas, A. K. (1997) · Immunity · doi:10.1016/s1074-7613(00)80284-8 · Cited by 716
Cited by
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
“Thus, not only do tumour masses 'escape' recognition by eliminating antigenic targets that they express, but they also co-opt or render insufficient the adaptive immune system of the hos”
BackgroundHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citationOverwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Self-citationGhiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
Self-citationSerafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
Self-citationDoes the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Self-citationWoo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Self-citationSerafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Self-citationThe role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Self-citationCancer Immunotherapy: A Treatment for the Masses
Blattman, J. N., & Greenberg, P. D. (2004) · Science · doi:10.1126/science.1100369 · Cited by 612
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
CD4 T Cells and Their Role in Antitumor Immune Responses
Toes, R. E. M., Ossendorp, F., Offringa, R., & Melief, C. J. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.753 · Cited by 508
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., & Zinkernagel, R. M. (2001) · Nature · doi:10.1038/35082583 · Cited by 493
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Fields, R. C., Shimizu, K., & Mulé, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9482 · Cited by 454
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
Egr-2 and Egr-3 are negative regulators of T cell activation
Safford, M., Collins, S., Lutz, M. A., Allen, A., Huang, C.-T., Kowalski, J., Blackford, A., Horton, M. R., Drake, C., Schwartz, R. H., et al. (2005) · Nature Immunology · doi:10.1038/ni1193 · Cited by 445
CD4 cells can be more efficient at tumor rejection than CD8 cells
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 437
Pardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Self-citationYang, Y., Huang, C.-T., Huang, X., & Pardoll, D. M. (2004) · Nature Immunology · doi:10.1038/ni1059 · Cited by 425
Self-citationSotomayor, E. M., Borrello, I., Tubb, E., Rattis, F.-M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., & Levitsky, H. I. (1999) · Nature Medicine · doi:10.1038/10503 · Cited by 407
Self-citationThe Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Self-citationFourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Eradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Liénard, D., Lejeune, F., Rimoldi, D., Guillaume, P., Meidenbauer, N., Mackensen, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3066 · Cited by 361
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Self-citationEradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
Dendritic cell dysfunction in cancer: A mechanism for immunosuppression
Pinzon‐Charry, A., Maxwell, T., & López, J. A. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01371.x · Cited by 328
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Workshop R: Tumor Immunology, Abstract R1 bis R30
(2001) · Immunobiology · doi:10.1016/s0171-2985(04)70018-2 · Cited by 312
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
Kusmartsev, S., Nagaraj, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4583 · Cited by 310
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Self-citationImmature myeloid cells and cancer-associated immune suppression
Kusmartsev, S., & Gabrilovich, D. I. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297
Features of responding T cells in cancer and chronic infection
Kim, P. S., & Ahmed, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.005 · Cited by 297
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
Drake, C. G., Doody, A. D. H., Mihalyo, M. A., Huang, C.-T., Kelleher, E., Ravi, S., Hipkiss, E. L., Flies, D. B., Kennedy, E. P., Long, M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.027 · Cited by 289
Self-citationCostimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Anandasabapathy (2003) · doi:10.1016/s1074-7613(03)00084-0 · Cited by 285
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Zhou, G., Drake, C. G., & Levitsky, H. I. (2006) · Blood · doi:10.1182/blood-2005-07-2737 · Cited by 272
Self-citationT cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α
Zha, Y., Marks, R., Ho, A. W., Peterson, A. C., Janardhan, S., Brown, I., Praveen, K., Stang, S., Stone, J. C., & Gajewski, T. F. (2006) · Nature Immunology · doi:10.1038/ni1394 · Cited by 267
Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey
ElTanbouly, M. A., & Noelle, R. J. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00454-2 · Cited by 265
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., & Dubinett, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.373 · Cited by 252
Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.795 · Cited by 252
Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy
Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., & Engleman, E. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7150 · Cited by 252
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
“As expected, IFN-g production by T cells cultured with WT macrophages was en- hanced in the presence of IL-10–neutralizing Abs (Fig.”
BackgroundMethodInfluentialSelf-citationTsukamoto, H., Fujieda, K., Hirayama, M., Ikeda, T., Yuno, A., Matsumura, K., Fukuma, D., Araki, K., Mizuta, H., Nakayama, H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2446 · Cited by 53
Metadata
- Authors
- Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-02-03
- Volume
- 95
- Issue
- 3
- Pages
- 1178-1183
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1987589866
- Cited by
- 704
- References
- 32
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.